Phenotypic spectrum associated with a CRADD founder variant underlying frontotemporal predominant pachygyria in the Finnish population.
Brain
/ diagnostic imaging
CRADD Signaling Adaptor Protein
/ genetics
Family Health
Female
Finland
Founder Effect
Genetic Predisposition to Disease
/ genetics
Geography
Homozygote
Humans
Lissencephaly
/ diagnostic imaging
Magnetic Resonance Imaging
/ methods
Male
Mutation, Missense
Pedigree
Phenotype
Exome Sequencing
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
28
09
2018
accepted:
07
03
2019
revised:
13
02
2019
pubmed:
28
3
2019
medline:
17
6
2020
entrez:
28
3
2019
Statut:
ppublish
Résumé
Intellectual disability (ID), megalencephaly, frontal predominant pachygyria, and seizures, previously called "thin" lissencephaly, are reported to be caused by recessive variants in CRADD. Among five families of different ethnicities identified, one homozygous missense variant, c.509G>A p.(Arg170His), was of Finnish ancestry. Here we report on the phenotypic variability associated for this potential CRADD founder variant in 22 Finnish individuals. Exome sequencing was used to identify candidate genes in Finnish patients presenting with ID. Targeted Sanger sequencing and restriction enzyme analysis were applied to screen for the c.509G>A CRADD variant in cohorts from Finland. Detailed phenotyping and genealogical studies were performed. Twenty two patients were identified with the c.509G>A p.(Arg170His) homozygous variant in CRADD. The majority of the ancestors originated from Northeastern Finland indicating a founder effect. The hallmark of the disease is frontotemporal predominant pachygyria with mild cortical thickening. All patients show ID of variable severity. Aggressive behavior was found in nearly half of the patients, EEG abnormalities in five patients and megalencephaly in three patients. This study provides detailed data about the phenotypic spectrum of patients with lissencephaly due to a CRADD variant that affects function. High inter- and intrafamilial phenotypic heterogeneity was identified in patients with pachygyria caused by the homozygous CRADD founder variant. The phenotype variability suggests that additional genetic and/or environmental factors play a role in the clinical presentation. Since frontotemporal pachygyria is the hallmark of the disease, brain imaging studies are essential to support the molecular diagnosis for individuals with ID and a CRADD variant.
Identifiants
pubmed: 30914828
doi: 10.1038/s41431-019-0383-8
pii: 10.1038/s41431-019-0383-8
pmc: PMC6777631
doi:
Substances chimiques
CRADD Signaling Adaptor Protein
0
CRADD protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1235-1243Commentaires et corrections
Type : ErratumIn
Références
Eur J Med Genet. 2012 Dec;55(12):753-7
pubmed: 23022981
Annu Rev Genet. 2011;45:81-104
pubmed: 21910631
Semin Cell Dev Biol. 2018 Apr;76:33-75
pubmed: 28951247
Exp Brain Res. 2006 Aug;173(2):322-33
pubmed: 16724181
Arch Neurol. 1979 Feb;36(2):88-94
pubmed: 420628
Nat Rev Genet. 2000 Dec;1(3):182-90
pubmed: 11252747
Neurology. 1983 Jan;33(1):57-66
pubmed: 6681560
Ann Med. 2011 May;43(3):235-48
pubmed: 20854213
Am J Med Genet A. 2017 Sep;173(9):2539-2544
pubmed: 28686357
Mech Ageing Dev. 2007 Feb;128(2):213-21
pubmed: 17188333
Biochem J. 2012 Jun 15;444(3):591-9
pubmed: 22515271
Nature. 1997 Jan 2;385(6611):86-9
pubmed: 8985253
Cell Death Differ. 2012 Aug;19(8):1370-80
pubmed: 22343713
Hum Genet. 2003 May;112(5-6):441-56
pubmed: 12627295
Clin Genet. 2014 Feb;85(2):101-10
pubmed: 23895455
Mol Psychiatry. 2017 Nov;22(11):1604-1614
pubmed: 27457812
Nat Genet. 2000 Sep;26(1):122-7
pubmed: 10973264
Genome Res. 1996 Sep;6(9):870-5
pubmed: 8889554
Am J Hum Genet. 2018 May 3;102(5):760-775
pubmed: 29706349
Nature. 1993 Aug 19;364(6439):717-21
pubmed: 8355785
PLoS One. 2012;7(1):e28936
pubmed: 22279524
Brain. 2012 May;135(Pt 5):1348-69
pubmed: 22427329
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Am J Med Genet C Semin Med Genet. 2014 Jun;166C(2):198-210
pubmed: 24862549
Duodecim. 1985;101(5):465-76
pubmed: 3987562
Annu Rev Genomics Hum Genet. 2010;11:161-87
pubmed: 20822471
Nat Commun. 2019 Jan 24;10(1):410
pubmed: 30679432
Am J Hum Genet. 2016 Nov 3;99(5):1117-1129
pubmed: 27773430
Mol Syndromol. 2016 Sep;7(4):220-233
pubmed: 27781032
Am J Med Genet A. 2017 Jun;173(6):1473-1488
pubmed: 28440899
Ann Med. 2012 Jun;44(4):369-74
pubmed: 21495784
Lancet Neurol. 2014 Jul;13(7):710-26
pubmed: 24932993
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14314-20
pubmed: 16183742
Nat Genet. 1999 Oct;23(2):233-6
pubmed: 10508524
Hum Mutat. 2013 Nov;34(11):1458-66
pubmed: 23904198
J Clin Invest. 1992 Jul;90(1):160-4
pubmed: 1634607